Imunon (IMNN) grants stock in lieu of salary to CMO

Rhea-AI Filing Summary

Faller Douglas Vincent reported acquisition or exercise transactions in this Form 4 filing.

Imunon, Inc. granted 3,082 shares of common stock to Chief Medical Officer Douglas Vincent Faller on July 17, 2026, valued at $1.83 per share. The stock was granted in lieu of cash for a portion of his base salary, and he now directly holds 26,286 shares of Imunon common stock.

Insider Trade Summary

Net Buyer: 3,082 shares

Net Buy 1 txn

Insider Faller Douglas Vincent

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	3,082	$1.83	$6K

Holdings After Transaction: Common Stock — 26,286 shares (Direct)

Footnotes (1)

1. F1. Stock granted in lieu of cash for portion of base salary

Key Figures

Shares granted: 3,082 shares Grant value per share: $1.83 per share Total shares after transaction: 26,286 shares

3 metrics

Shares granted 3,082 shares Common stock granted to CMO on July 17, 2026

Grant value per share $1.83 per share Value assigned to the July 17, 2026 stock grant

Total shares after transaction 26,286 shares Direct Imunon common stock holdings of the CMO after the grant

Key Terms

grant, award, or other acquisition, in lieu of cash, base salary

3 terms

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

in lieu of cash financial

"Stock granted in lieu of cash for portion of base salary"

base salary financial

"Stock granted in lieu of cash for portion of base salary"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/21/2026 - 04:15 PM Accepted by SEC EDGAR 07/21/2026 - 04:15 PM Learn about SEC filing dates

FAQ

What insider transaction involving Imunon (IMNN) and Douglas Vincent Faller was reported?

Douglas Vincent Faller, Imunon’s chief medical officer, received a grant of 3,082 common shares on July 17, 2026. The stock was issued as part of his compensation package, replacing cash for a portion of his base salary rather than being a market purchase.

How many Imunon (IMNN) shares were granted to the CMO and at what price?

Imunon granted its CMO 3,082 shares of common stock at a value of $1.83 per share. These shares were issued as stock in lieu of cash salary, reflecting compensation terms rather than an open-market transaction or discretionary share purchase.

Is the Imunon (IMNN) CMO’s new stock position from a market buy or compensation grant?

The CMO’s new shares come from a compensation grant, not a market purchase. The shares were granted in lieu of cash for a portion of his base salary, indicating an equity-based salary component rather than active trading in Imunon stock.

What is Douglas Vincent Faller’s Imunon (IMNN) share ownership after the latest grant?

After the July 17, 2026 grant, Douglas Vincent Faller directly holds 26,286 Imunon common shares. This total reflects his position following receipt of 3,082 additional shares issued as stock compensation in place of cash for part of his base salary.

Was the Imunon (IMNN) CMO’s stock grant made under a Rule 10b5-1 trading plan?

The report indicates the transaction was not made under a Rule 10b5-1 plan. The 10b5-1 checkbox is shown as unchecked, and the grant is described as stock issued in lieu of cash salary, rather than a trade executed under a preset trading program.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Faller Douglas Vincent

(Last) (First) (Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE NEW JERSEY 08648

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/17/2026		A		3,082(1)	A	$1.83	26,286	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Stock granted in lieu of cash for portion of base salary

	/s/ Susan Eylward, Attorney-in-Fact for Douglas Faller	07/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)